TrialOncotarget2015

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.

Liang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.